Zogenix names new board member
This article was originally published in Scrip
Executive Summary
San Diego-based Zogenix, a pharmaceutical company developing products for the treatment of pain-related conditions and central nervous system disorders, has named Dr James B Breitmeyer to its board of directors. Dr Breitmeyer currently serves as president of Bavarian Nordic, a late-stage biotechnology company. He is also executive vice-president of Bavarian A/S, a multinational corporation headquartered in Denmark which specializes in the research, development and manufacturing of vaccines and immunotherapy regimens for biodefense, infectious diseases and oncology. He has also previously served as acting chief medical officer of Zogenix in an advisory capacity.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.